Roswell Park and Generate Biomedicines have dosed the first patient in a phase 1 trial of GB-5267, an AI-designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results